Cytosorbents (CTSO) Short term Debt (2016 - 2026)

Cytosorbents' (CTSO) quarterly Short term Debt came in at $6.6 million in Q1 2026, up 165.84% on a QoQ basis from $2.5 million in Q1 2024.

Cytosorbents (CTSO) Short term Debt (2016 - 2026) Analysis & Trends

Cytosorbents (CTSO) has 8 years of Short term Debt data on file, last reported at $6.6 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (changed N/A YoY) and the FY2023 annual result came in at $2.5 million, changed N/A from the prior year.
Short term Debt rose to $6.6 million in Q1 2026, from $2.5 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $6.6 million in Q1 2026 to a low of $833333.0 in Q3 2023.
A 3-year average of $3.1 million and a median of $2.5 million in 2023 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Cytosorbents	19.47 Mn	15.06 Mn	7.05 Mn

Download Data